William Rote, Retrophin, Inc. (RTRX)’s insider Unloaded 1,985 Shares; Magnetar Financial Upped Marathon Pete (MPC) Stake By $14.75 Million

Marathon Petroleum Corporation (NYSE:MPC) Logo

Magnetar Financial Llc increased Marathon Pete Corp (MPC) stake by 38.32% reported in 2018Q3 SEC filing. Magnetar Financial Llc acquired 182,125 shares as Marathon Pete Corp (MPC)’s stock declined 26.02%. The Magnetar Financial Llc holds 657,403 shares with $53.28 million value, up from 475,278 last quarter. Marathon Pete Corp now has $43.97 billion valuation. The stock increased 2.88% or $1.78 during the last trading session, reaching $63.65. About 4.14 million shares traded. Marathon Petroleum Corporation (NYSE:MPC) has declined 4.72% since February 14, 2018 and is downtrending. It has underperformed by 4.72% the S&P500. Some Historical MPC News: 30/04/2018 – Marathon Petroleum to buy Andeavor in $36bn energy deal; 17/05/2018 – DGAP-NEWS: MPC CAPITAL AG: KEY FIGURES FOR THE 1ST QUARTER 2018; 06/05/2018 – INDIA’S GARG SEES NO BIAS IN MPC TO RAISE INTEREST RATES: PTI; 28/03/2018 – S. AFRICA’S KGANYAGO: MPC SEES RISK TO GROWTH OUTLOOK ON UPSIDE; 22/05/2018 – BANK OF ENGLAND’S CARNEY SAYS MPC HAS HAD “RIGOROUS” DISCUSSION OF PUBLISHING INTEREST RATE PATH, MAJORITY OF MPC NOT IN FAVOUR; 07/03/2018 – Marathon Petroleum Coverage Assumed by Credit Suisse at Outperform; 22/05/2018 – BANK OF ENGLAND MPC’S VLIEGHE SAYS BREXIT UNCERTAINTY IS HAVING A DAMPENING EFFECT ON SOME OF THE ECONOMY; 13/03/2018 – NIGERIA SENATE AGREES TO SCREEN MPC NOMINEES FOR APPROVAL; 18/04/2018 – Fluor Awarded Contract for Marathon Petroleum’s STAR Program at Galveston Bay Refinery; 04/04/2018 – VEERATHAI: THAI MPC RATE-DECISION SPLIT ISN’T SOMETHING NEW

Magnetar Financial Llc decreased Thermo Fisher Scientific Inc (NYSE:TMO) stake by 5,384 shares to 964 valued at $235,000 in 2018Q3. It also reduced Bjs Whsl Club Hldgs Inc stake by 24,818 shares and now owns 75,182 shares. Amphenol Corp New (NYSE:APH) was reduced too.

More notable recent Marathon Petroleum Corporation (NYSE:MPC) news were published by: Seekingalpha.com which released: “Marathon Petroleum Before Earnings – Seeking Alpha” on February 06, 2019, also Seekingalpha.com with their article: “Marathon Petroleum declares $0.53 dividend – Seeking Alpha” published on January 28, 2019, Benzinga.com published: “Marathon Petroleum Corporation (NYSE:MPC), Exxon Mobil Corporation (NYSE:XOM) – Port Report: Refiner Inaction Seen Ahead Of IMO 2020, But Some Planning For New Fuel Rules – Benzinga” on February 04, 2019. More interesting news about Marathon Petroleum Corporation (NYSE:MPC) were released by: Globenewswire.com and their article: “Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications – GlobeNewswire” published on January 22, 2019 as well as Seekingalpha.com‘s news article titled: “Will The Rally Of Marathon Petroleum Resume? – Seeking Alpha” with publication date: October 10, 2018.

Among 7 analysts covering Marathon Petroleum (NYSE:MPC), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Marathon Petroleum had 10 analyst reports since September 7, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Friday, September 7 by Citigroup. Morgan Stanley maintained Marathon Petroleum Corporation (NYSE:MPC) on Tuesday, November 20 with “Overweight” rating. Citigroup maintained the stock with “Buy” rating in Tuesday, October 16 report. The rating was reinitiated by PiperJaffray with “Overweight” on Thursday, January 10. Barclays Capital maintained Marathon Petroleum Corporation (NYSE:MPC) on Wednesday, October 3 with “Overweight” rating. Morgan Stanley maintained the stock with “Overweight” rating in Friday, October 12 report. Citigroup maintained it with “Buy” rating and $95 target in Thursday, December 6 report.

Since October 9, 2018, it had 3 insider buys, and 0 selling transactions for $384,121 activity. DAVIS STEVEN A bought $155,500 worth of stock or 2,500 shares. Goff Gregory James also bought $11,131 worth of Marathon Petroleum Corporation (NYSE:MPC) on Tuesday, October 9.

Investors sentiment increased to 1.24 in 2018 Q3. Its up 0.30, from 0.94 in 2018Q2. It is positive, as 34 investors sold MPC shares while 306 reduced holdings. 131 funds opened positions while 289 raised stakes. 385.13 million shares or 7.58% more from 358.01 million shares in 2018Q2 were reported. Capital Advsrs Limited Llc owns 150 shares for 0% of their portfolio. Rowland & Com Counsel Adv owns 1,984 shares. Whittier Com Of Nevada holds 19,708 shares. Cls Invests Ltd Liability reported 45 shares or 0% of all its holdings. Bankshares Of America De invested in 4.02M shares or 0.05% of the stock. Jacobs And Ca holds 5,065 shares or 0.07% of its portfolio. First State Bank Of Mount Dora Tru Inv Svcs reported 2,800 shares. Gabelli Funds Lc has 0.22% invested in Marathon Petroleum Corporation (NYSE:MPC). 48,000 were reported by Quantres Asset Management. Wilen Invest Corporation reported 34,046 shares. Gotham Asset Mgmt Ltd Liability reported 16,885 shares stake. Peapack Gladstone Corporation has 4,067 shares. Prudential Public Limited Co holds 0% or 6,354 shares. Sta Wealth Mgmt Ltd Liability Corporation has invested 0.12% in Marathon Petroleum Corporation (NYSE:MPC). Hrt Fincl Limited Liability holds 198,637 shares.

Analysts await Retrophin, Inc. (NASDAQ:RTRX) to report earnings on February, 26. They expect $-0.62 earnings per share, down 58.97% or $0.23 from last year’s $-0.39 per share. After $-1.34 actual earnings per share reported by Retrophin, Inc. for the previous quarter, Wall Street now forecasts -53.73% EPS growth.

More notable recent Retrophin, Inc. (NASDAQ:RTRX) news were published by: Nasdaq.com which released: “Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results – Nasdaq” on February 12, 2019, also Nasdaq.com with their article: “Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results – Nasdaq” published on February 04, 2019, Seekingalpha.com published: “New chief at Retrophin – Seeking Alpha” on January 03, 2019. More interesting news about Retrophin, Inc. (NASDAQ:RTRX) were released by: Globenewswire.com and their article: “Retrophin Provides Corporate Update and 2019 Outlook Nasdaq:RTRX – GlobeNewswire” published on January 07, 2019 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive – Benzinga” with publication date: January 29, 2019.

The Senior Vice President – R&D of Retrophin Inc, William Rote is in the stock market news today. It was stated in a legal document filled by William Rote and submitted to the D.C. based-SEC on February 13, 2019, he unloaded 1,985 shares from the firm worth near $42,558 U.S Dollars. The mentioned shares average price was $21.4. William Rote now owns 16,007 shares or 0.04% of Retrophin Inc’s market cap.

Investors sentiment decreased to 1.08 in 2018 Q3. Its down 0.24, from 1.32 in 2018Q2. It dived, as 16 investors sold Retrophin, Inc. shares while 34 reduced holdings. 22 funds opened positions while 32 raised stakes. 41.12 million shares or 2.80% more from 40.01 million shares in 2018Q2 were reported. Invesco Ltd reported 0.01% stake. Product Prtnrs Limited holds 66,052 shares or 0.08% of its portfolio. Moreover, Palisade Cap Ltd Nj has 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX) for 8,500 shares. Shell Asset Mngmt invested 0% in Retrophin, Inc. (NASDAQ:RTRX). Bogle Inv Mgmt L P De reported 105,859 shares stake. California State Teachers Retirement Systems holds 0% of its portfolio in Retrophin, Inc. (NASDAQ:RTRX) for 61,896 shares. Dimensional Fund Advsrs Limited Partnership owns 1.09 million shares for 0.01% of their portfolio. Geode Capital Management Limited Company has 0% invested in Retrophin, Inc. (NASDAQ:RTRX) for 458,615 shares. Amer International Group Inc Inc, New York-based fund reported 26,840 shares. 2,838 were reported by Zurcher Kantonalbank (Zurich Cantonalbank). Credit Suisse Ag owns 61,296 shares. Jefferies Grp Limited Liability Company owns 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX) for 50,000 shares. Millennium Mgmt Ltd holds 0.02% in Retrophin, Inc. (NASDAQ:RTRX) or 519,619 shares. Rock Springs Cap Mngmt Lp accumulated 400,000 shares. Moreover, Virginia Retirement Sys Et Al has 0.01% invested in Retrophin, Inc. (NASDAQ:RTRX).

The stock decreased 3.47% or $0.77 during the last trading session, reaching $21.44. About 255,037 shares traded. Retrophin, Inc. (NASDAQ:RTRX) has risen 11.46% since February 14, 2018 and is uptrending. It has outperformed by 11.46% the S&P500.

Since August 31, 2018, it had 0 insider buys, and 11 selling transactions for $2.03 million activity. Clague Laura also sold $164,665 worth of Retrophin, Inc. (NASDAQ:RTRX) on Thursday, December 20. Another trade for 5,000 shares valued at $120,130 was sold by ROTE WILLIAM E. McFarlane Neil F. also sold $248,333 worth of Retrophin, Inc. (NASDAQ:RTRX) on Thursday, December 20. 11,100 shares were sold by ASELAGE STEVE, worth $266,703 on Wednesday, November 14. REED ELIZABETH E had sold 1,500 shares worth $35,933.

Among 3 analysts covering Retrophin (NASDAQ:RTRX), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Retrophin has $57 highest and $36 lowest target. $45.67’s average target is 113.01% above currents $21.44 stock price. Retrophin had 3 analyst reports since August 17, 2018 according to SRatingsIntel.

Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases. The company has market cap of $884.35 million. The Company’s marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. It currently has negative earnings. The company??s product candidates consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Tetracosactide Zinc , a synthetic hormone analog that is in preclinical stage; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in preclinical stage to treat primary biliary cholangitis.

Marathon Petroleum Corporation (NYSE:MPC) Institutional Positions Chart